Rab46: a novel player in mast cell function
Discovery Immunology · 01.01.2024 · 3 (1)
DOI: 10.1093/discim/kyad028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discovery Immunology, online erschienen am 22.12.2023. Verfasst von Lucia Pedicini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Mast cells are infamous for mediating allergic and inflammatory diseases due to their capacity of rapidly releasing a wide range of inflammatory mediators stored in cytoplasmic granules. However, mast cells also have several important physiological roles that involve selective and agonist-specific release of these active mediators. While a filtering mechanism at the plasma membrane could regulate the selective release of some cargo, the plethora of stored cargo and the diversity of mast cell functions suggests the existence of granule subtypes with distinct trafficking pathways. The molecular mechanisms underlying differential trafficking and exocytosis of these granules are not known, neither is it clear how granule trafficking is coupled to the stimulus. In endothelial cells, a Rab GTPase, Rab46, responds to histamine but not thrombin signals, and this regulates the trafficking of a subpopulation of endothelial-specific granules. Here, we sought to explore, for the first time, if Rab46 plays a role in mast cell function. We demonstrate that Rab46 is highly expressed in human and murine mast cells, and Rab46 genetic deletion has an effect on mast cell degranulation that depends on both stimuli and mast cell subtype. This initial insight into the contribution of Rab46 to mast cell function and the understanding of the role of Rab46 in stimuli-dependent trafficking in other cell types necessitates further investigations of Rab46 in mast cell granular trafficking so that novel and specific therapeutic targets for treatment of the diverse pathologies mediated by mast cells can be developed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
- Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK.
- National Institute for Health Research-Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, UK.
ORCID-Profile: Sinisa Savic, Lynn McKeown
Förderung
- Medical Research Council
Zitieren
APA
Pedicini, L., Smith, J., Savic, S., & McKeown, L. (2024). Rab46: a novel player in mast cell function. Discovery Immunology, 3(1). https://doi.org/10.1093/discim/kyad028
Vancouver
Pedicini L, Smith J, Savic S, McKeown L. Rab46: a novel player in mast cell function. Discovery Immunology. 2024;3(1). doi:10.1093/discim/kyad028
BibTeX
@article{Pedicini2024,
author = {Pedicini, Lucia and Smith, Jessica and Savic, Sinisa and McKeown, Lynn},
title = {Rab46: a novel player in mast cell function},
journal = {Discovery Immunology},
year = {2024},
volume = {3},
number = {1},
doi = {10.1093/discim/kyad028}
}
EUVIMED